文献速递中毒与环境急症重症综合管理与镇静镇痛

新型苯二氮䓬类溴唑仑的临床特征:ASSIST(非法物质毒性监测研究)数据

Clinical characterisation of the novel benzodiazepine bromazolam-data from the ASSIST (A Surveillance Study of Illicit Substance Toxicity) study.
PubMed 文献 · Clin Toxicol (Phila) · 2025-07-28
一句话结论在苏格兰格拉斯哥急诊就诊的中重度非法药物毒性成人中,45.8%检出溴唑仑,检出率从第1季度22.7%升至第6季度58.3%,最常见表现为意识下降(79.6%),12.4%需重症监护。

该观察性研究于2022年8月17日至2024年2月16日在格拉斯哥伊丽莎白女王大学医院开展,利用ASSIST监测研究(NCT05329142)数据,纳入急诊就诊的中重度非法药物毒性且溴唑仑检测阳性的成人。在1188例成人就诊中,653例符合毒理学分析条件,其中299例(45.8%)涉及溴唑仑,检出率从第1季度22.7%升至第6季度58.3%。溴唑仑阳性样本中位年龄42岁(IQR 34-50岁),男性214例(71.6%),中位检出非法物质数为7种(IQR 5-9种)。最常见临床特征为意识下降(238例,79.6%),37例(12.4%)需重症监护入院。结论指出高比例物质共用限制了对溴唑仑特异性毒性的完全归因,但研究突出了其在该人群中的流行率及阳性检出者的临床特征。

要点

  • 在653例符合毒理学分析条件的急诊成人中,299例(45.8%)检出溴唑仑,检出率从第1季度22.7%升至第6季度58.3%。
  • 溴唑仑阳性样本中位检出7种非法物质(IQR 5-9种),高比例物质共用使临床特征难以完全归因于溴唑仑。
  • 溴唑仑阳性者最常见临床特征为意识下降(238例,79.6%),37例(12.4%)需重症监护入院。
  • 溴唑仑阳性者中位年龄42岁(IQR 34-50岁),男性214例(71.6%)。
  • 研究期间溴唑仑检出率上升与苏格兰药物死亡数据一致。

适用人群与场景

  • 苏格兰格拉斯哥伊丽莎白女王大学医院急诊就诊的成人(≥18岁),表现为中重度非法物质毒性且溴唑仑检测阳性者被纳入。
  • 研究期间为2022年8月17日至2024年2月16日。

研究设计与关键结果

  • 观察性研究,单中心(伊丽莎白女王大学医院,格拉斯哥),纳入1188例成人非法药物毒性就诊,其中653例符合毒理学分析条件。
  • 653例中299例(45.8%)检出溴唑仑,检出率从第1季度22.7%升至第6季度58.3%。
  • 溴唑仑阳性样本中位年龄42岁(IQR 34-50岁),男性214例(71.6%)。
  • 溴唑仑阳性样本中位检出非法物质数为7种(IQR 5-9种)。
  • 最常见临床特征为意识下降(238例,79.6%),37例(12.4%)需重症监护入院。
  • 毒理学分析采用超高效液相色谱与Thermofisher Q-Exactive Orbitrap高分辨精确质量系统联用,在政府化学家实验室Assure实验室对匿名样本进行。

证据类型、等级与局限

  • 证据类型:观察性研究(基于ASSIST监测研究,NCT05329142)。
  • 局限:高比例物质共用限制了对溴唑仑特异性毒性特征的完全归因(原文讨论与结论均指出)。

对床旁实践的改变

  • 在苏格兰格拉斯哥急诊就诊的中重度非法药物毒性成人中,溴唑仑检出率在研究期间从22.7%升至58.3%,提示该人群溴唑仑暴露常见。
  • 溴唑仑阳性者中位检出7种非法物质,临床特征不能完全归因于溴唑仑单药。
  • 溴唑仑阳性者意识下降常见(79.6%),12.4%需重症监护入院。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Scotland has a drug death crisis. In 2023, 58% of drug-related deaths involved benzodiazepines. Novel benzodiazepines, predominantly bromazolam, are found in the drug "street valium", commonly used in Scotland. This study describes features of analytically confirmed bromazolam use.

METHODS: This observational study was conducted at the Queen Elizabeth University Hospital, Glasgow between 17 August 2022 and 16 February 2024. The study used data from a larger surveillance study (A Surveillance Study of Illicit Substance Toxicity, clinicaltrials.gov, NCT05329142). Emergency department attendances with moderate to severe illicit substance toxicity and positive detection of bromazolam were included. Toxicological analysis was performed on anonymised samples in the Laboratory of the Government Chemist Assure laboratory using ultra performance liquid chromatography interfaced with Thermofisher Q-Exactive Orbitrap high resolution accurate mass systems. The study has full ethical approval (West of Scotland Research Ethics Committee 22/WS/0047).

RESULTS: Of 1,188 adult attendances with illicit drug toxicity, 653 qualified for toxicological analysis. Two-hundred ninety-nine (45.8%) of these involved bromazolam with increasing rates seen within this study from 22.7% in quarter 1 to 58.3% in quarter 6. The median age was 42 years (IQR: 34-50 years) and 214 (71.6%) were male. The median number of illicit substances detected in samples with bromazolam was seven (IQR: five to nine). The most common clinical feature was reduced consciousness (238 patients, 79.6%) and 37 patients (12.4%) required critical care admission.

DISCUSSION: Rates of bromazolam detection increased within the population studied, aligning with Scottish drug death figures. Though clinical features presented in this study cannot be fully attributed to bromazolam alone due to high substance co-use, reduced consciousness was frequent.

CONCLUSION: High rates of substance co-use inhibit our ability to fully understand specific features of bromazolam toxicity, however, this study highlights its prevalence in this population and identifies clinical features in positive detections.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Dunlop LC, Craik V, Jarvie N, et al. Clinical characterisation of the novel benzodiazepine bromazolam-data from the ASSIST (A Surveillance Study of Illicit Substance Toxicity) study. Clin Toxicol (Phila). 2025. PMID: 40719187. doi:10.1080/15563650.2025.2524078

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。